KPIs & Operating Metrics(New)
Breakdown Of AssetsContractual ObligationsCost Of SalesEmployee StatisticsGross Margin %Gross Margin Annual %Gross ProfitGross Profit AnnualIncome Before Income TaxesNon Gaap ProfitabilityNon Gaap Profitability %Non Gaap Profitability AnnualNon Gaap Profitability Annual %Operating Expense SegregationOpex As A % Of RevenueProperty, Plant & Equipment, Net BreakdownR&D As A %R&D SegregationRevenueRevenue By Customer TypeRevenue By Customer Type %Revenue By ProductRevenue By Product %Revenue By Product AnnualRevenue By Product Annual %Revenue By SegmentRevenue By Segment %
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Acadia Pharmaceuticals (ACAD) Revenue (2016 - 2025)

Acadia Pharmaceuticals has reported Revenue over the past 16 years, most recently at $284.0 million for Q4 2025.

  • Quarterly results put Revenue at $284.0 million for Q4 2025, up 9.39% from a year ago — trailing twelve months through Dec 2025 was $1.1 billion (up 11.87% YoY), and the annual figure for FY2025 was $1.1 billion, up 11.87%.
  • Revenue for Q4 2025 was $284.0 million at Acadia Pharmaceuticals, up from $278.6 million in the prior quarter.
  • Over the last five years, Revenue for ACAD hit a ceiling of $284.0 million in Q4 2025 and a floor of $106.6 million in Q1 2021.
  • Median Revenue over the past 5 years was $185.5 million (2023), compared with a mean of $187.9 million.
  • Biggest five-year swings in Revenue: dropped 0.68% in 2022 and later skyrocketed 73.75% in 2024.
  • Acadia Pharmaceuticals' Revenue stood at $130.8 million in 2021, then increased by 4.38% to $136.5 million in 2022, then skyrocketed by 69.27% to $231.0 million in 2023, then grew by 12.36% to $259.6 million in 2024, then rose by 9.39% to $284.0 million in 2025.
  • The last three reported values for Revenue were $284.0 million (Q4 2025), $278.6 million (Q3 2025), and $264.6 million (Q2 2025) per Business Quant data.